<DOC>
	<DOCNO>NCT02979119</DOCNO>
	<brief_summary>Rationale : Haemophilia rare disease ; improve knowledge international collaboration need . Well-defined clinical data collect complete cohort order prevent selection bias . Objective : To collect data bleed neonatal period , endogenous ( genetic ) exogenous ( treatment-related ) determinant inhibitor development long term outcome .</brief_summary>
	<brief_title>The European Paediatric Network Haemophilia Management ( PedNet Registry )</brief_title>
	<detailed_description>Design : Prospective observational cohort Population : Patients haemophilia A B FVIII/IX level &lt; 1 25 % born 1-1-2000 1-1-2020 . Intervention : No intervention ; documentation patient characteristic parameter routine patient care outcome Main outcome parameter : Outcome : clinically relevant inhibitor development , bleed pattern joint status physical examination imaging . Determinants : baseline FVIII/IX level , measurement inhibitory antibody , family history , FVIII/IX gene mutation , detail replacement therapy ( accord infusion first 50 treatment day , annually thereafter ) surgery . Nature extent burden risk associate participation , benefit group relatedness : - No burden patient . Well-defined clinical data collect medical file . Participating registry change number visit clinic . All outcome parameter collect ( include laboratory result ) part routine clinical care . - Direct benefit expect . However , direct interaction centre treat patient rare diseases improve clinical care result well guideline may provide indirect benefit . - Multicentre participation : haemophilia rare condition . Therefore , collect data multi-centre observational cohort way study specific population . - The registry concern young boy haemophilia perform old patient , &gt; 90 % inhibitor occur develop first 50 exposure day , result prophylactic replacement therapy highly dependent initiation treatment .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Diagnosed Haemophilia A B Factor VIII/ IX activity &lt; 1 25 % Complete record Factor treatment bleeds Treated one participating centre Patients refer inhibitor* Informed consent obtain</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hemophilia</keyword>
	<keyword>Children , ,</keyword>
	<keyword>Inhibitors ,</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Long-term outcome</keyword>
	<keyword>Congenital</keyword>
</DOC>